Abstract
To characterize Parkinson disease, abnormal phase-amplitude coupling is assessed in the cortico-basal circuit using invasive recordings. Whether the same phenomenon might be found in areas other than the cortico-basal ganglia circuit is unknown. We hypothesized that using magnetoencephalography to assess phase-amplitude coupling in the whole brain can characterize Parkinson disease. We recorded resting-state magnetoencephalographic signals in patients with Parkinson disease and in healthy age- and sex-matched participants. We compared the whole-brain signals from the two groups, evaluating the power spectra of 3 frequency bands (alpha, 8–12 Hz; beta, 13–25 Hz; gamma, 50–100 Hz) and the coupling between the gamma amplitude and the alpha or beta phases. Compared with the healthy participants, the patients with Parkinson disease showed significant beta–gamma phase-amplitude coupling in the sensorimotor, occipital, and temporal cortices. In contrast, the two groups showed no significant difference in their resting-state powers. Further, in a resting state, the beta–gamma phase-amplitude coupling in the sensorimotor cortices correlated significantly with motor symptoms of Parkinson disease (P < 0.05); the beta-band power did not. We thus demonstrated that beta–gamma phase-amplitude coupling in the resting state characterizes Parkinson disease.
Introduction
Parkinson’s Disease (PD) is traditionally associated with "dysrhythmia" in the brain's cortico-basal ganglia circuits. A primary indicator of this dysrhythmia is abnormal Phase-Amplitude Coupling (PAC)—a phenomenon where the phase of a low-frequency oscillation (such as beta waves) regulates the strength (amplitude) of a high-frequency oscillation (such as gamma waves).
Historically, detecting abnormal PAC has required invasive intracranial electrodes, typically during surgeries for Deep Brain Stimulation (DBS). While electroencephalography (EEG) offers a non-invasive alternative, its low spatial resolution limits the ability to pinpoint signal origins. This study investigates whether Magnetoencephalography (MEG)—a non-invasive technique with high temporal and superior spatial resolution—can map PAC across the whole brain and serve as a reliable biomarker for Parkinsonian symptoms.
Methods
The study compared brain activity between PD patients and healthy controls using a 160-channel whole-head MEG system.
Participants and Clinical Data
The study involved a clinical dataset collected at Osaka University Hospital, consisting of 23 PD patients and 23 age- and sex-matched healthy study participants (HSPs). Clinical severity for the PD group was measured using the MDS-UPDRS-III akinesia score. Anatomical T1-weighted MRI scans were utilized for individual head modeling.
Data Analysis
- Resting-State Recording: Participants were recorded for over 240 seconds in a resting state with eyes closed.
- Source Imaging: Using MRI-based source reconstruction, electrical currents were estimated across 360 distinct cortical areas based on the Human Connectome Project (HCP) map.
- Synchronization Index (SI): PAC was quantified using a Synchronization Index, measuring how the high-frequency gamma amplitude (50–100 Hz) locks to the phase of lower-frequency alpha (8–12 Hz) or beta (13–25 Hz) oscillations.
- Power Analysis: Standard power spectra for alpha, beta, and gamma bands were also calculated for comparison.
Key Results and Insights
PAC as a Superior Biomarker
The study found that standard "power" (the intensity of beta or gamma activity) did not significantly differ between PD patients and healthy controls. However, the coupling between these frequencies was significantly higher in the PD group. This suggests that the coordination between brain regions is more indicative of PD than the sheer magnitude of the signals.
Cortical Distribution
Exaggerated beta-gamma PAC was not confined to the motor cortex. It was also detected in the occipital (visual) and temporal cortices. This represents the first report of exaggerated PAC in the occipital cortex for PD, potentially providing a link to non-motor symptoms such as visual perception issues.
Clinical Correlation
In the sensorimotor cortex, the strength of the beta-gamma coupling (SI) positively correlated with patients' akinesia scores ($r = 0.45, P = 0.022$). In contrast, beta-band power in the same regions showed no correlation with symptoms ($r = -0.02, P = 0.943$), highlighting PAC's unique value as a clinical biomarker.
Discussion and Limitations
While these results are promising, several factors must be considered. Most patients remained on dopamine agonists during the study; since these medications are known to suppress PAC, the study likely underestimated the true extent of abnormal coupling. Additionally, MEG is highly sensitive to movement and muscle artifacts, which led to the exclusion of several participants.
Future research may utilize non-invasive PAC monitoring to track disease progression or evaluate treatment efficacy without the need for invasive surgery. Further exploration into the link between occipital PAC and visual hallucinations in PD is also warranted.
Summary updated